Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPT vs IMRT in Locally Advanced Nasopharyngeal Carcinoma
NCT07340515Phase 3Recruiting
- Sponsor
- Nanjing Manhua Biotechnology
- Start
- Dec 2025
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Nanjing Manhua Biotechnology. Primary endpoints: Incidence of treatment-related grade ≥3 acute toxicities at 90 days and Progression-Free Survival at 3 years. Started Dec 2025; status: recruiting.
02
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07340515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340515.